Abstract
In mammalian cells, Id proteins coordinate proliferation and differentiation. Id2 is a dominant-negative antagonist of basic helix–loop–helix transcription factors and proteins of the retinoblastoma (Rb) family. Here we show that Id2–Rb double knockout embryos survive to term with minimal or no defects in neurogenesis and haematopoiesis, but they die at birth from severe reduction of muscle tissue. In neuroblastoma, an embryonal tumour derived from the neural crest, Id2 is overexpressed in cells carrying extra copies of the N-myc gene. In these cells, Id2 is in molar excess of the active form of Rb. The overexpression of Id2 results from transcriptional activation by oncoproteins of the Myc family. Cell-cycle progression induced by Myc oncoproteins requires inactivation of Rb by Id2. Thus, a dual connection links Id2 and Rb: during normal cell-cycle, Rb prohibits the action of Id2 on its natural targets, but oncogenic activation of the Myc–Id2 transcriptional pathway overrides the tumour-suppressor function of Rb.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
196,21 € per year
only 3,85 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout








Similar content being viewed by others
References
Norton, J. D., Deed, R. W., Craggs, G. & Sablitzky, F. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol. 8, 58–65 (1998 ).
Massari, M. E. & Murre, C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol. Cell. Biol. 20, 429–440 (2000).
Iavarone, A., Garg, P., Lasorella, A., Hsu, J. & Israel, M. A. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev. 8, 1270–1284 (1994).
Lasorella, A., Iavarone, A. & Israel, M. A. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol. Cell. Biol. 16, 2570–2578 (1996).
Clarke, A. R. et al. Requirement for a functional Rb-1 gene in murine development. Nature 359, 328–330 (1992).
Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295–300 (1992).
Lee, E. Y. -H. P. et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and hematopoesis. Nature 359, 288– 294 (1992).
Zacksenhaus, E. et al. pRb controls proliferation, differentiation, and death of skeletal muscle cells and other lineages during embryogenesis. Genes Dev. 10, 3051–3064 (1996).
Lee, E. Y. et al. Dual roles of the retinoblastoma protein in cell cycle regulation and neuron differentiation. Genes Dev. 8, 2008–2021 (1994).
Jen, Y., Manova, K. & Benezra, R. Each member of the Id gene family exhibits a unique expression pattern in mouse gastrulation and neurogenesis. Dev. Dyn. 208, 92–106 ( 1997).
Neuman, T. et al. Neuronal expression of regulatory helix-loop-helix factor Id2 gene in mouse. Dev. Biol. 160, 186– 195 (1993).
Zhu, W. et al. Id gene expression during development and molecular cloning of the human Id-1 gene. Brain Res. Mol. Brain Res. 30, 312–326 (1995).
Sherr, C. J. Cancer cell cycles. Science 274, 1672– 1677 (1996).
Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell 81, 323–330 (1995).
Martinsen, B. J. & Bronner-Fraser, M. Neural crest specification regulated by the helix-loop-helix repressor Id2. Science 281, 988–991 ( 1998).
Maris, J. M. & Matthay, K. K. Molecular biology of neuroblastoma. J. Clin. Oncol. 17, 2264– 2279 (1999).
Easton, J., Wei, T., Lahti, J. M. & Kidd, V. J. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res. 58, 2624–2632 (1998).
Beltinger, C. P., White, P. S., Sulman, E. P., Maris, J. M. & Brodeur, G. M. No CDKN2 mutations in neuroblastomas. Cancer Res. 55, 2053-2055 ( 1995).
Diccianni, M. B., Chau, L. S., Batova, A., Vu, T. Q. & Yu, A. L. The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. Cancer Lett. 104, 183–192 (1996).
Diccianni, M. B. et al. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma. Int. J. Cancer 80, 145–154 (1999).
Castresana, J. S., Gomez, L., Garcia-Miguel, P., Queizan, A. & Pestana, A. Mutational analysis of the p16 gene in human neuroblastomas. Mol. Carcinog. 18, 129–133 (1997).
Kawamata, N., Seriu, T., Koeffler, H. P. & Bartram, C. R. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas. Cancer 77, 570–575 (1996).
Fan, X., Gomez, L., Nistal, M., Sierrasesumaga, L. & Castresana, J. S. Lack of gene amplification as a mechanism of CDK4 activation in human neuroblastoma. Oncol. Rep. 6, 647–650 (1999).
Alevizopoulos, K., Vlach, J., Hennecke, S. & Amati, B. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J. 16, 5322–5333 (1997).
Goodrich, D. W. & Lee, W. H. Abrogation by c-Myc of G1 phase arrest induced by RB protein but not by p53 [published erratum: Nature 360, 491 ( 1992)]. Nature 360, 177– 179 (1992).
Amati, B., Alevizopoulos, K. & Vlach, J. Myc and the cell cycle. Front Biosci. 3, D250–268 (1998).
Slack, R. S., El-Bizri, H., Wong, J., Belliveau, D. J. & Miller, F. D. A critical temporal requirement for the retinoblastoma protein family during neuronal determination. J. Cell Biol. 140, 1497–1509 (1998).
Iavarone, A. & Massague, J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 387, 417– 422 (1997).
Pietenpol, J. A. et al. TGF-β1 Inhibition of c-Myc transcription and growth in keratinocytes is abrogated by viral transforming protein with pRB binding domeins. Cell 61, 777–785 (1990).
Neuman, K., Nornes, H. O. & Neuman, T. Helix-loop-helix transcription factors regulate Id2 gene promoter activity. FEBS Lett. 374, 279–283 (1995).
Boyd, K. E., Wells, J., Gutman, J., Bartley, S. M. & Farnham, P. J. c-Myc target gene specificity is determined by a post-DNA-binding mechanism. Proc. Natl Acad. Sci. USA 95, 13887–13892 (1998).
Morrow, M. A., Mayer, E. W., Perez, C. A., Adlam, M. & Siu, G. Overexpression of the Helix-Loop-Helix protein Id2 blocks T cell development at multiple stages. Mol. Immunol. 36, 491–503 ( 1999).
Florio, M. et al. Id2 promotes apoptosis by a novel mechanism independent of dimerization to basic helix-loop-helix factors. Mol. Cell. Biol. 18, 5435–5444 ( 1998).
Cooper, C. L., Brady, G., Bilia, F., Iscove, N. N. & Quesenberry, P. J. Expression of the Id family helix-loop-helix regulators during growth and development in the hematopoietic system. Blood 89, 3155–3165 ( 1997).
Tsai, K. Y. et al. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell 2, 293–304 ( 1998).
Jen, Y., Manova, K. & Benezra, R. Expression patterns of Id1, Id2, and Id3 are highly related but distinct from that of Id4 during mouse embryogenesis. Dev. Dyn. 207, 235–252 ( 1996).
Yokota, Y. et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397, 702–706 (1999).
Lufkin, T. et al. Homeotic transformation of the occipital bones of the skull by ectopic expression of a homeobox gene. Nature 359 , 835–841 (1992).
Jacobs, J. J., Kieboom, K., Marino, S., DePinho, R. A. & van Lohuizen, M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397, 164–168 ( 1999).
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 ( 1997).
Iavarone, A. & Massague, J. E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Mol. Cell. Biol. 19, 916– 922 (1999).
Acknowledgements
We thank Y. Yokota and T. Jacks for providing us with Id2+/- and Rb+/- mice, respectively; R. Russell for support in the preparation of pathological specimens and histological consultation; J. Massague for the Mv1Lu cell line expressing tetracycline-inducible c-Myc; E. Latres for p15-/- MEFs; C. Thiele for human neuroblastoma cell lines; R. Pestell for c-MycER cDNA; N. Schreiber-Agus for N-myc cDNA; M. van Lohuizen for LZRS-GFP retroviruses; and S. Lowe for retroviral vectors encoding activated ras and E1A. This work was supported by a grant from AIRC (Associazione Italiana per la Ricerca sul Cancro) to A.L., a grant from NIH (R01 to A.I.) and an institutional research grant from the American Cancer Society (A.I.). A.I. is recipient of a Sinsheimer Scholar award and M.N. is supported by a fellowship from Fondazione Beatrice Angelini.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
About this article
Cite this article
Lasorella, A., Noseda, M., Beyna, M. et al. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407, 592–598 (2000). https://doi.org/10.1038/35036504
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/35036504
This article is cited by
-
Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma
Oncogene (2022)
-
The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer
Experimental & Molecular Medicine (2022)
-
Id proteins: emerging roles in CNS disease and targets for modifying neural stemcell behavior
Cell and Tissue Research (2022)
-
Anti-tumor effects of an ID antagonist with no observed acquired resistance
npj Breast Cancer (2021)
-
Functional genomics identifies new synergistic therapies for retinoblastoma
Oncogene (2020)